Share Price and Basic Stock Data
Last Updated: February 10, 2026, 10:39 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
MPS Pharmaa Ltd operates within the pharmaceuticals sector, a space that has faced significant challenges in recent years. The company reported a share price of ₹1.68 and a market capitalization of ₹3.21 Cr. However, MPS Pharmaa has not generated any revenue from operations since at least March 2022, with reported sales standing at ₹0.00 for the trailing twelve months (TTM). This stark absence of sales highlights a critical issue in its business operations. The company has seen a consistent decline in sales from ₹30.27 Cr in March 2014 to ₹0.00 by March 2025. This downward trend in revenue is concerning, especially in an industry that typically experiences steady growth due to ongoing healthcare needs. The lack of operational revenue raises questions about the company’s business model and its ability to regain a foothold in the market.
Profitability and Efficiency Metrics
The profitability metrics for MPS Pharmaa Ltd are alarming, as the company has reported consistent net losses over several financial periods. The net profit for March 2025 stood at a loss of ₹0.90 Cr, reflecting a significant decline from a loss of ₹0.14 Cr in March 2022. The interest coverage ratio (ICR) is particularly concerning, recorded at an astonishing -1438.08x for March 2025, indicating that the company is unable to cover its interest expenses. The return on equity (ROE) was reported at 59.0%, but this figure is misleading since it is derived from negative net profits, suggesting a high level of financial distress. The operational profit margin (OPM) has remained negative, with no signs of recovery. In an industry where positive margins are critical for sustainability, MPS Pharmaa’s inability to generate profits raises serious concerns about its operational efficiency and long-term viability.
Balance Sheet Strength and Financial Ratios
MPS Pharmaa’s balance sheet reveals significant weaknesses, particularly in its reserves and borrowings. The company reported reserves of -₹18.47 Cr, indicating a negative net worth, which is a red flag for potential investors. Total borrowings stood at ₹7.51 Cr, contributing to a high debt-to-equity ratio of 6.90x as of March 2025, which far exceeds typical sector norms. This high leverage amplifies financial risk, especially when combined with negative profitability metrics. The current ratio is low at 0.25, suggesting that the company may struggle to meet its short-term liabilities. Furthermore, the book value per share has declined to ₹0.56, down from ₹2.00 in March 2022, which further illustrates the degradation of shareholder equity. The combination of negative reserves, high debt, and low liquidity positions MPS Pharmaa in a precarious financial situation.
Shareholding Pattern and Investor Confidence
The shareholding pattern of MPS Pharmaa Ltd reflects a concentration of ownership, with promoters holding 35.89% of the company. Institutional investments are minimal, with domestic institutional investors (DIIs) owning only 0.58%, while foreign institutional investors (FIIs) have no reported holdings. The public holds 63.52% of shares, a significant portion that indicates a broad base of retail investors. However, the declining number of shareholders, which fell from 4,512 in December 2022 to 4,433 by September 2025, suggests waning investor confidence. The absence of dividends since 2014 further dissuades potential investors. With such a high proportion of public ownership and the lack of institutional backing, MPS Pharmaa faces challenges in stabilizing its stock price and attracting new investments.
Outlook, Risks, and Final Insight
The outlook for MPS Pharmaa Ltd appears bleak given its persistent lack of revenue, negative profitability, and deteriorating financial health. Key risks include its inability to generate operational income, high leverage, and potential liquidity issues. If the company fails to implement a successful turnaround strategy, it may face severe financial distress or insolvency. However, if MPS Pharmaa can address its operational inefficiencies and begin generating revenue, it may have a chance to recover. The company’s high ROE could be a signal of potential for future profitability if leveraged correctly. Ultimately, the next steps taken by management will be critical in determining whether MPS Pharmaa can stabilize its operations and restore investor confidence in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 128 Cr. | 102 | 174/84.3 | 28.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,593 Cr. | 330 | 479/192 | 75.2 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 30.8 Cr. | 41.5 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 81.4 Cr. | 55.6 | 55.6/17.0 | 194 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,009.19 Cr | 1,116.87 | 53.37 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.24 | 0.23 | 0.31 | 0.19 | 0.21 | 0.18 | 0.21 | 0.19 | 0.19 | 0.18 | 0.19 | 0.19 | 0.19 |
| Operating Profit | -0.24 | -0.23 | -0.31 | -0.19 | -0.21 | -0.18 | -0.21 | -0.19 | -0.19 | -0.18 | -0.19 | -0.19 | -0.19 |
| OPM % | |||||||||||||
| Other Income | 0.00 | 0.00 | 0.02 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.28 | -0.27 | -0.33 | -0.20 | -0.19 | -0.22 | -0.25 | -0.23 | -0.23 | -0.18 | -0.23 | -0.23 | -0.23 |
| Tax % | 0.00% | 0.00% | -3.03% | -5.00% | -5.26% | -4.55% | 0.00% | -4.35% | -4.35% | 0.00% | 21.74% | -4.35% | -4.35% |
| Net Profit | -0.27 | -0.26 | -0.32 | -0.19 | -0.18 | -0.21 | -0.24 | -0.22 | -0.22 | -0.17 | -0.28 | -0.22 | -0.22 |
| EPS in Rs | -0.14 | -0.14 | -0.17 | -0.10 | -0.09 | -0.11 | -0.13 | -0.12 | -0.12 | -0.09 | -0.15 | -0.12 | -0.12 |
Last Updated: January 6, 2026, 8:06 pm
Below is a detailed analysis of the quarterly data for MPS Pharmaa Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.19 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.19 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.19 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.19 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.23 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.23 Cr..
- For Tax %, as of Sep 2025, the value is -4.35%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -4.35%.
- For Net Profit, as of Sep 2025, the value is -0.22 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.22 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.12. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.27 | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 27.43 | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.75 |
| Operating Profit | 2.84 | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.75 |
| OPM % | 9.38% | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| Other Income | 0.01 | 0.00 | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 |
| Interest | 1.20 | 1.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.68 | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.16 |
| Profit before tax | 0.97 | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -0.87 |
| Tax % | 50.52% | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | |
| Net Profit | 0.46 | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -0.89 |
| EPS in Rs | 0.31 | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -247.83% | -75.00% | -521.01% | 88.23% | -43.68% | 6.40% | -277.78% | 96.83% | -650.00% | 20.95% | -8.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 172.83% | -446.01% | 609.24% | -131.91% | 50.08% | -284.18% | 374.61% | -746.83% | 670.95% | -29.39% |
MPS Pharmaa Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | -24% |
| 5 Years: | -44% |
| 3 Years: | -39% |
| Last Year: | -59% |
Last Updated: September 5, 2025, 3:51 pm
Balance Sheet
Last Updated: December 4, 2025, 3:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 5.05 | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -18.47 |
| Borrowings | 8.22 | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.51 |
| Other Liabilities | 6.52 | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.84 |
| Total Liabilities | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
| Fixed Assets | 15.18 | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.74 |
| CWIP | 0.00 | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.65 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Other Assets | 18.72 | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 2.06 |
| Total Assets | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
Below is a detailed analysis of the balance sheet data for MPS Pharmaa Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.11 Cr..
- For Reserves, as of Sep 2025, the value is -18.47 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -18.03 Cr. (Mar 2025) to -18.47 Cr., marking a decline of 0.44 Cr..
- For Borrowings, as of Sep 2025, the value is 7.51 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 7.46 Cr. (Mar 2025) to 7.51 Cr., marking an increase of 0.05 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.84 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.80 Cr. (Mar 2025) to 0.84 Cr., marking an increase of 0.04 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.99 Cr.. The value appears to be improving (decreasing). It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.74 Cr.. The value appears to be declining and may need further review. It has decreased from 3.83 Cr. (Mar 2025) to 3.74 Cr., marking a decrease of 0.09 Cr..
- For CWIP, as of Sep 2025, the value is 2.65 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2025) to 2.65 Cr., marking a decrease of 0.26 Cr..
- For Investments, as of Sep 2025, the value is 0.54 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.54 Cr..
- For Other Assets, as of Sep 2025, the value is 2.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.06 Cr..
- For Total Assets, as of Sep 2025, the value is 8.99 Cr.. The value appears to be declining and may need further review. It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
However, the Borrowings (7.51 Cr.) are higher than the Reserves (-18.47 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.38 | -6.97 | -7.14 | -9.78 | -3.43 | -3.24 | -3.20 | -9.82 | -6.49 | -7.72 | -8.07 | -8.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104.30 | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | |||||
| Inventory Days | 94.81 | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | ||||
| Days Payable | 62.46 | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | ||||
| Cash Conversion Cycle | 136.65 | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | |||||
| Working Capital Days | 99.72 | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | |||||
| ROCE % | 8.18% | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Diluted EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Cash EPS (Rs.) | -0.39 | -0.35 | -0.47 | 0.19 | -2.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| PBDIT / Share (Rs.) | -0.37 | -0.36 | -0.48 | -0.21 | -2.06 |
| PBIT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| PBT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| Net Profit / Share (Rs.) | -0.46 | -0.43 | -0.54 | -0.07 | -2.31 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -1290.32 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -2876.76 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -2880.22 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -437.31 | 0.00 |
| Return on Networth / Equity (%) | -83.08 | -42.21 | -37.63 | -3.70 | -111.78 |
| Return on Capital Employeed (%) | -68.24 | -38.85 | -35.47 | -22.83 | -96.84 |
| Return On Assets (%) | -9.62 | -8.36 | -10.31 | -1.39 | -39.07 |
| Total Debt / Equity (X) | 6.90 | 3.69 | 2.42 | 1.52 | 0.48 |
| Current Ratio (X) | 0.25 | 0.27 | 0.29 | 0.33 | 0.32 |
| Quick Ratio (X) | 0.19 | 0.20 | 0.22 | 0.24 | 0.24 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.08 | 0.03 | 0.00 |
| Interest Coverage Ratio (X) | -1438.08 | -563.32 | -1722.46 | -373.22 | -7579.04 |
| Interest Coverage Ratio (Post Tax) (X) | -1800.93 | -662.72 | -1955.76 | -125.49 | -8500.46 |
| Enterprise Value (Cr.) | 13.53 | 13.40 | 10.77 | 8.45 | 3.35 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 261.01 | 0.00 |
| EV / EBITDA (X) | -18.88 | -19.00 | -11.65 | -20.23 | -0.85 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 82.05 | 0.00 |
| Price / BV (X) | 5.63 | 3.12 | 1.44 | 0.69 | 0.36 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 86.88 | 0.00 |
| EarningsYield | -0.14 | -0.13 | -0.26 | -0.05 | -3.08 |
After reviewing the key financial ratios for MPS Pharmaa Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.39. This value is below the healthy minimum of 3. It has decreased from -0.35 (Mar 24) to -0.39, marking a decrease of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.37. This value is below the healthy minimum of 2. It has decreased from -0.36 (Mar 24) to -0.37, marking a decrease of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 2. It has decreased from -0.43 (Mar 24) to -0.46, marking a decrease of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -83.08. This value is below the healthy minimum of 15. It has decreased from -42.21 (Mar 24) to -83.08, marking a decrease of 40.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is -68.24. This value is below the healthy minimum of 10. It has decreased from -38.85 (Mar 24) to -68.24, marking a decrease of 29.39.
- For Return On Assets (%), as of Mar 25, the value is -9.62. This value is below the healthy minimum of 5. It has decreased from -8.36 (Mar 24) to -9.62, marking a decrease of 1.26.
- For Total Debt / Equity (X), as of Mar 25, the value is 6.90. This value exceeds the healthy maximum of 1. It has increased from 3.69 (Mar 24) to 6.90, marking an increase of 3.21.
- For Current Ratio (X), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 1.5. It has decreased from 0.27 (Mar 24) to 0.25, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.20 (Mar 24) to 0.19, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1,438.08. This value is below the healthy minimum of 3. It has decreased from -563.32 (Mar 24) to -1,438.08, marking a decrease of 874.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1,800.93. This value is below the healthy minimum of 3. It has decreased from -662.72 (Mar 24) to -1,800.93, marking a decrease of 1,138.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.53. It has increased from 13.40 (Mar 24) to 13.53, marking an increase of 0.13.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -18.88. This value is below the healthy minimum of 5. It has increased from -19.00 (Mar 24) to -18.88, marking an increase of 0.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 5.63. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 5.63, marking an increase of 2.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.14. This value is below the healthy minimum of 5. It has decreased from -0.13 (Mar 24) to -0.14, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MPS Pharmaa Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -68.24% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -83.08% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1800.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.19
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.37)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 6.9
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 138, Roz-Ka-Meo Industrial Area, Sohna, Mewat Dist. Haryana 122103 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Peeyush Kumar Aggarwal | Managing Director |
| Mr. Ram Niwas Sharma | Non Independent Director |
| Ms. Madhu Sharma | Independent Director |
| Mr. Ajay Sharma | Independent Director |
FAQ
What is the intrinsic value of MPS Pharmaa Ltd?
MPS Pharmaa Ltd's intrinsic value (as of 12 February 2026) is ₹2.22 which is 32.14% higher the current market price of ₹1.68, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3.21 Cr. market cap, FY2025-2026 high/low of ₹4.15/1.68, reserves of ₹-18.47 Cr, and liabilities of ₹8.99 Cr.
What is the Market Cap of MPS Pharmaa Ltd?
The Market Cap of MPS Pharmaa Ltd is 3.21 Cr..
What is the current Stock Price of MPS Pharmaa Ltd as on 12 February 2026?
The current stock price of MPS Pharmaa Ltd as on 12 February 2026 is ₹1.68.
What is the High / Low of MPS Pharmaa Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MPS Pharmaa Ltd stocks is ₹4.15/1.68.
What is the Stock P/E of MPS Pharmaa Ltd?
The Stock P/E of MPS Pharmaa Ltd is .
What is the Book Value of MPS Pharmaa Ltd?
The Book Value of MPS Pharmaa Ltd is 0.33.
What is the Dividend Yield of MPS Pharmaa Ltd?
The Dividend Yield of MPS Pharmaa Ltd is 0.00 %.
What is the ROCE of MPS Pharmaa Ltd?
The ROCE of MPS Pharmaa Ltd is 9.79 %.
What is the ROE of MPS Pharmaa Ltd?
The ROE of MPS Pharmaa Ltd is 59.0 %.
What is the Face Value of MPS Pharmaa Ltd?
The Face Value of MPS Pharmaa Ltd is 10.0.